Callan Family Office’s Elanco Animal Health ELAN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.93M Sell
164,316
-2,871
-2% -$70.2K 0.09% 228
2025
Q4
$3.78M Buy
167,187
+7,866
+5% +$171K 0.08% 230
2025
Q3
$3.21M Sell
159,321
-6,877
-4% -$115K 0.1% 204
2025
Q2
$2.37M Buy
166,198
+117,174
+239% +$1.37M 0.07% 253
2025
Q1
$515K Buy
49,024
+12,304
+34% +$139K 0.04% 315
2024
Q4
$445K Buy
+36,720
New +$480K 0.03% 393
2023
Q2
Sell
-11,500
Closed -$108K 126
2023
Q1
$108K Buy
+11,500
New +$136K 0.03% 152

Other funds holding ELAN

Callan Family Office's ELAN Position: Q1 2026 in Review

Callan Family Office reduced its Elanco Animal Health (ELAN) stake by 1.7% in Q1 2026, selling an estimated $70.2K and leaving 164,316 shares worth $3.93M. The position accounts for 0.09% of the portfolio, ranked #228.

Callan Family Office first reported a position in ELAN in Q1 2023 and has held it in 7 quarters since. 515 funds tracked by Wall St. Rank hold ELAN as of Q1 2026.

  • Callan Family Office held 164,316 shares of Elanco Animal Health worth $3.93M as of Q1 2026.
  • Callan Family Office sold 2,871 Elanco Animal Health shares in Q1 2026, an estimated $70.2K.
  • Elanco Animal Health made up 0.09% of Callan Family Office's portfolio in Q1 2026, its #228 holding.
  • Callan Family Office first reported a position in Elanco Animal Health in Q1 2023 and has held it in 7 quarters since.
  • 515 funds tracked by Wall St. Rank held Elanco Animal Health as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.